Trials / Unknown
UnknownNCT05420519
Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
A Phase I Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Chongqing Precision Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with advanced/metastatic renal cell carcinoma, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Detailed description
This is a single-center, single-arm, open-label study. Intravenous infusion group have 4 dose groups, adopting a dose-escalating 3+3 design, and plan to recruit about 12 subjects with CD70-positive advanced/metastatic renal cell carcinoma in Dose discovery phase and 12 subjects in dose expansion phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD70 CAR-T cells | Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion. |
Timeline
- Start date
- 2021-12-31
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2022-06-15
- Last updated
- 2023-08-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05420519. Inclusion in this directory is not an endorsement.